Why myopia management is often a cash-pay expense in the U.S.
Standard vision insurance in the United States was designed around corrective lenses and routine eye exams. The newer category of myopia management - which includes specialty contact lenses, prescription eye drops used for myopia control, and serial axial length monitoring - falls largely outside the scope of most traditional vision benefit plans.
This doesn't mean coverage is impossible. Medical insurance, vision insurance, and FSA or HSA accounts each have different rules, and coverage varies by plan, by state, and by how services are coded and documented. But many families do pay some or all of these costs out of pocket, and understanding what drives the total helps with planning and with the conversation you'll have with your child's doctor.
A note on insurance: Ask your insurer specifically whether axial length biometry, specialty myopia-control contact lenses, and compounded atropine drops are covered under your plan. Ask your eye care provider what documentation they submit and whether a medical insurance pathway is available in their practice. The answers vary - and asking directly is the only reliable way to know.
The main cost drivers in myopia management
Myopia management isn't a single service - it's a program with several components, each of which has its own cost structure. Here are the main categories to understand.
Axial length biometry
Measuring axial length requires an optical biometer - a specialized device not available in every practice. Depending on the practice's fee schedule and payer rules, this measurement may be included in the visit fee or charged separately.
Specialty contact lenses
Myopia-control contact lenses (such as dual-focus daily disposables or orthokeratology lenses) are designed differently from standard lenses and carry higher per-unit or fitting costs.
Atropine eye drops
Low-dose atropine for myopia is used off-label in the U.S. and is typically compounded by a pharmacy. Coverage for compounded or off-label use varies by plan - many families pay out of pocket. Prices vary across compounding pharmacies.
Follow-up visit frequency
Active myopia management typically requires visits every 6 months rather than annually. Each visit may include refraction, axial length measurement, and a clinical consultation - each potentially billed separately.
Myopia-control spectacle lenses
Some spectacle lens designs intended for myopia management (including DIMS-based and highly aspherical lenslet–based designs) are priced higher than standard lenses but generally lower than specialty contact lens programs on an annual basis. Availability and regulatory status vary by country and product.
Clinical consultation and documentation
The clinical interpretation of progression data, treatment planning, and parent counseling takes meaningful time. Practices that invest in this typically charge for the consultation as a distinct service.
Questions to ask your eye care provider
Coming to an appointment with specific questions helps you understand both the clinical picture and the practical costs involved. Here are questions worth asking - not to challenge the doctor, but to have a complete picture.
Myopia management approaches and their general cost tier
The following table provides a general framework for thinking about options. It is not a recommendation, and it does not reflect specific prices, which vary significantly by location, practice, and insurance coverage. Efficacy data shown reflects published axial-length reduction in peer-reviewed trials - not all treatments perform equally for all children.
Educational information only. This table does not provide medical advice, diagnosis, or treatment recommendations. Myopia management options, risks, benefits, and follow-up intervals must be determined by a licensed eye-care professional based on an individual child's examination and clinical history. Published study results describe groups of participants and do not predict an individual child's outcome.
Important: A lower cost does not mean a less appropriate option, and a higher cost does not guarantee better results. Treatment selection should be guided by your child's specific clinical profile, not cost alone. Discuss all options with your eye care provider.
| Approach | General cost tier | Published AL efficacy | Notes |
|---|---|---|---|
| Outdoor time 1–2+ hrs/day natural light |
No direct cost | Strong evidence for reducing myopia onset risk in children without myopia. Evidence for slowing progression in established myopia is less consistent. | Reasonable low-cost adjunct to any treatment program. Evidence supports onset prevention; discuss progression benefit with your provider. |
| Standard spectacle correction Single-vision lenses |
Typically covered | Not a myopia management treatment - corrects vision but does not slow progression | Necessary for clear vision but does not address progression. Often a starting point. |
| Myopia-control spectacle lenses DIMS-based and highly aspherical lenslet designs; availability and regulatory status vary by country and product |
Low–Moderate | In a 2-year RCT, DIMS lenses produced less axial elongation than single-vision controls (Lam et al. Br J Ophthalmol. 2020). In a separate 2-year study, a highly aspherical lenslet design produced less axial elongation than single-vision controls (Bao et al. JAMA Ophthalmol. 2022). Results from separate trials should not be compared directly. | May have a lower total annual out-of-pocket cost than some daily disposable contact-lens programs, depending on lens design, fitting fees, and insurance allowances. No lens handling required. Verify availability and current labeling status in the U.S. with the prescribing clinician. |
| Low-dose atropine drops 0.01% – 0.05% compounded |
Low–Moderate | 0.05% atropine showed the strongest axial-length effect among the low-dose concentrations tested in the LAMP trial (Yam et al. Ophthalmology 2019); reported effect sizes vary by year and study design and should not be used to predict an individual child's response. 0.01%: In the LAMP trial, 0.01% atropine showed modest slowing at year 1; a separate U.S. placebo-controlled trial (PEDIG 2023) did not support efficacy at this concentration in the population studied. That result applies specifically to the 0.01% formulation and population examined; it should not be interpreted as evidence about other concentrations or formulations. |
Coverage for compounded or off-label use varies by plan - many families pay out of pocket. Compounding pharmacy costs vary. Requires a prescription. Safety note: can cause light sensitivity, pupil dilation, near-vision blur, and irritation; compounded formulations may differ in vehicle, preservative, and stability. Discuss risks and monitoring with your prescribing clinician. |
| Myopia-control soft contact lenses MiSight, dual-focus designs |
Moderate | In a 3-year randomized controlled trial, MiSight wearers had less axial elongation than single-vision contact lens wearers (Chamberlain et al. Optom Vis Sci. 2019). This is a group-level result from one trial and should not be used to predict an individual child's response. | Daily disposables; no overnight wear. Annual supply cost is ongoing. Appropriate for motivated children typically 8+ years old. Safety note: requires daily lens hygiene and adherence; treatment suitability depends on the child's ocular health and clinician assessment. |
| Orthokeratology (Ortho-K) Overnight rigid lenses |
Moderate–Higher | Multiple trials have shown less axial elongation with Ortho-K vs. single-vision controls, with reductions varying by study. Results from separate trials should not be compared directly. | Higher upfront fitting cost; may have lower ongoing supply cost than daily lenses. Requires careful fitting and regular follow-up. Safety note: overnight rigid lens wear carries a risk of corneal infection; hygiene and follow-up compliance are essential. Not appropriate for all children. |
| Combination therapy e.g., Ortho-K + atropine |
Higher | Some smaller studies suggest that selected combinations may provide additional slowing compared with monotherapy; evidence is more limited than for individual treatments and treatment decisions require clinician oversight. | Reserved for higher-risk cases. Evidence for combination is from smaller studies. Costs combine those of each component. |
How to read the evidence: Trial results differ in age, baseline myopia, treatment duration, comparator, adherence, ethnicity, geography, refraction methods, and whether the outcome is axial length or refractive error. Percentage reductions from separate trials should not be compared as if they were a head-to-head study, and group results do not predict individual outcomes. Availability, regulatory authorization, and labeling requirements vary by country and product. Verify current status with a licensed eye-care provider.
FSA and HSA accounts may help
Flexible Spending Accounts (FSA) and Health Savings Accounts (HSA) allow you to pay for eligible medical expenses with pre-tax dollars. Some myopia management expenses - including prescription eye exams, prescribed contact lenses, and prescription eye drops - may be eligible if they are medically necessary and prescribed by a qualified provider. Eligibility depends on your specific plan, account type, and IRS rules in effect at the time of purchase.
Confirm eligibility with your FSA or HSA plan administrator before assuming coverage. Ask specifically whether specialty myopia-control contact lenses and compounded atropine qualify under your account - the answer depends on your plan and whether the items are prescribed. Keep receipts and prescription documentation for reimbursement purposes.
If your employer offers an FSA or HSA: setting aside even a modest amount annually can meaningfully offset the out-of-pocket cost of biometry visits and specialty lenses, since these expenses are predictable and recurring.
How tracking helps you get more from every visit
Regardless of which treatment your child is on, one of the most practical things you can do is maintain a clear record of their axial length measurements and prescription history over time. When a clinician can see the full longitudinal picture at the start of an appointment, the consultation can focus on decisions rather than reconstruction.
Track measurements across every visit
Store OD and OS axial length, refraction, and treatment details for each visit. See the growth trend visualized against normative percentile curves for your child's age.
Generate a visit-preparation summary
Produce a one-page summary of entered measurements and treatment history to share with your child's eye-care clinician. This is a visit-preparation aid - it is not a substitute for the clinician's record, diagnosis, or treatment plan.
Understand the clinical context
The built-in calculator shows where your child's axial length sits relative to published norms for their age, sex, and ethnicity - giving you the context to understand what the numbers mean.
Come to appointments prepared
Having a clear history of prior measurements, treatments, and responses lets you have a more informed conversation with your child's eye care provider - and helps the clinician spend consultation time on decisions rather than data entry.
When to seek prompt eye care
Myopia management appointments are scheduled in advance, but some eye symptoms should not wait for a routine visit. Seek urgent eye care - or contact your child's eye-care professional promptly - if your child experiences any of the following:
This list is not exhaustive. If you are uncertain whether a symptom is urgent, contact your child's eye-care professional for guidance. This page does not provide emergency or urgent-care advice.
What to bring to each myopia management visit
Having this information ready helps the clinician spend appointment time on clinical decisions rather than reconstructing history.
Frequently asked questions
Why is myopia management often not covered by insurance?
Most U.S. vision insurance plans were designed around corrective lenses and routine eye exams. Myopia management treatments - including specialty contact lenses, atropine drops prescribed off-label for myopia, and axial length biometry monitoring - fall outside the scope of traditional vision benefit plans in most cases.
Medical insurance coverage depends on individual policy terms, diagnosis coding, and the specific services provided. Families should verify coverage directly with their insurer and ask their eye care provider what documentation may be required. The situation is not static - coverage for myopia management is an area of active discussion in the U.S. eye care community.
Is atropine for myopia covered by insurance?
Coverage for off-label or compounded use varies by plan - many families pay out of pocket, though some plans cover compounded medications with a valid prescription. Families should ask their insurer and pharmacist directly. Compounding pharmacies vary in price; confirming quality and accreditation standards before ordering from an unfamiliar provider is advisable.
Are there options that cost less but still have clinical evidence?
Yes. Outdoor time in natural daylight has been shown in multiple large trials to reduce the risk of myopia onset in children who do not yet have myopia (He et al. JAMA 2015; Rose et al. Ophthalmology 2008). It has no direct cost. The evidence for slowing progression in children who already have established myopia is considerably weaker and less consistent - this distinction is important. It is, however, widely recommended as a reasonable low-cost adjunct to active treatment.
Some myopia-control spectacle lens designs have published evidence comparable to contact lens options, at generally lower annual cost. Discussing the full range of evidence-based options with your provider - including relative costs - is a reasonable part of treatment planning.
What does "off-label" mean for atropine, and is it safe?
"Off-label" means a drug is used for a purpose not included in its FDA-approved labeling. This is legal and common in medicine - many pediatric medications are used off-label because the FDA approval process is based on studies in adults.
Low-dose atropine (0.01% to 0.05%) has been studied in multiple large randomized controlled trials, including the LAMP studies in Hong Kong and the PEDIG trial in the U.S. These trials provide safety and efficacy data that clinicians use to inform off-label prescribing decisions. The decision to use atropine should be made in consultation with a qualified eye care provider who can weigh the evidence and your child's specific situation.
Can I get axial length measurements at any eye doctor?
Not at every practice. Axial length biometry requires a specialized optical device (such as an IOLMaster or Lenstar) that is not standard equipment in all optometry offices. Practices that offer myopia management programs are more likely to have this equipment.
If your current provider does not offer biometry, you can ask for a referral to a practice that does. Having axial length measured is valuable for tracking progression over time - a prescription alone does not capture the full picture of myopia progression.
How often does my child need to be seen if they're in a myopia management program?
Many clinicians review children approximately every six months; earlier or more frequent follow-up may be appropriate based on age, progression rate, treatment type, ocular findings, and clinician judgment. Discuss the right follow-up schedule for your child's situation with their provider - this varies between children and can change over time.
More frequent visits increase annual costs but also increase the likelihood of detecting a treatment that isn't working and adjusting it before more progression occurs. Discussing the appropriate follow-up interval for your child's specific situation with their provider is important.
Is myopia management worth the cost?
This is a clinical and personal decision, not one this page can answer for any individual family. What the evidence shows is that higher adult axial lengths are associated with meaningfully higher lifetime risks of serious eye conditions including myopic maculopathy, retinal detachment, and glaucoma (Tideman et al. JAMA Ophthalmol. 2016). Slowing the rate of elongation during childhood can reduce where a child ends up in adulthood.
The clinical decision about whether to treat, what to treat with, and how intensively - and the financial decision about what is feasible - belongs with you and your child's eye care provider. This page is intended to help you ask better questions and understand the landscape, not to make that decision for you.
Reliable resources for parents
The following organizations publish patient-facing information on myopia that is reviewed by clinical professionals:
Citations
Organize your child's axial length history
MyopiaTracker is free to start. Enter measurements from each visit to see longitudinal trend visualizations and generate a visit-preparation summary to share with your child's eye-care clinician.
About MyopiaTracker: MyopiaTracker organizes user-entered historical measurements and presents them graphically for discussion with an eye-care professional. It does not diagnose myopia, determine treatment eligibility, interpret clinical findings, replace biometry or refraction performed by a clinician, or provide treatment recommendations. Estimated trend scenarios reflect user-entered data only and are not clinical predictions.